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Detection and resection of small neuroendocrine tumours (NET) is like finding a needle in a hay stack. Use of specific tracers such 
as 68Ga-DOTATOC in a PET/CT study has been proven to have a high sensitivity and specificity to cells expressing somatostatin-
SSR receptors. The use of 99mTc-Octreotide to detect neuroendocrine tumours during surgery is an effective adjunct for therapy. 
We here present a clinical case of patient with NET where these modalities help in both diagnostic and therapeutic surgery.
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Neuroendocrine tumors (NET) are common GI tu-
mors and their detection and resection is like finding 
a needle in a hay stack. Nuclear medicine is a potential 
imaging tool which can be used for both diagnostic and 
therapeutic purposes. Many imaging modalities used 
in the past have a low sensitivity for NET compared 
to 68Ga-DOTATOC [1]. Computed tomography with 
contrast can detect only up to 30% of tumors with a size 
of 1–3 cm [2]. Imaging techniques such as magnetic res-
onance imaging and computed tomography are not very 
adequate in detection of neuroendocrine tumours [3]. 
Use of specific tracers such as 68Ga-DOTATOC in a PET/
CT study has been proven to have a high sensitivity and 
specificity to cells expressing somatostatin receptors [5]. 
The use of 99mTc-Octreotide to detect neuroendocrine 
tumors during surgery is an effective adjunct for therapy. 
We here present a clinical case where these modalities 
help in both diagnostic and therapeutic surgery.
Case report. In June, 2008, a 54-year-old man 
was referred to us with the diagnosis of urothelial car-
cinoma of the bladder (transitional cell carcinoma). 
After clinical investigations and confirmation of the 
diagnosis, he underwent a laparoscopic resection 
of the urinary bladder and prostate gland together 
with dissection and clearance of pelvic lymph nodes. 
During follow-up, in January 2010, biopsy was done 
on a suspicious paracaval lymph node. Histology re-
vealed it to be a lymph node metastases of NET which 
did not originate from the bladder. MRI, endoscopic ul-
trasound, esophago-gastro-duodenal endoscopy, and 
colonoscopy were performed, but no primary NET was 
found. Besides this, the tumor marker chromogramin-
A was low. The patient was considered to have cancer 
of unknown primary. However, the resected lymph 
node presented an elevated number of somatostatin 
receptors which are typically found in NET. Hence, 
a PET/CT scan was performed with 68Ga-DOTATOC 
which is highly sensitive to SSR2-receptors. We found 
an increased uptake in paravertebral lymph node and 
in a small area located in the duodenum. We have 
successfully nailed down the primary tumor — but 
how could we help our surgical colleagues to resect 
the suspicious tumor?
We decided with our surgical team to proceed with 
gamma radiation probe guided surgery (Fig. 1). 
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Fig. 1. a, b) Gamma probe used during surgical procedure 
detecting the neuroendocrine tumor; CT and co-registered 
PET/CT images obtained before (c, d) and 4 months after suc-
cessful surgical tumor resection (e, f)
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99mTc-Octreotide is also sensitive to SSR2 but 
emits gamma-rays instead of positrons as 68Ga. The 
gamma probe was effectively used to help us detect-
ing radiation emitted by the tumor intraoperatively 
and provided real-time information to navigate for 
tumour localization [1]. After surgical procedure the 
resected specimen was reported to be a 1.8 cm well-
differentiated neuroendocrine (Fig. 2) carcinoma 
of the papilla limited to the duodenal wall and two 
peripancreatic lymph node metastases. Four months 
later on a follow-up 68Ga-DOTATOC PET/CT imaging 
showed no suspicious lesion (Fig. 1).
Pathologic examination of the resected specimen 
confirmed as a 1.8 cm tumor of whitish cut surface 
and firm consistency, locating at the papilla (Fig. 2). 
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Fig. 2. a) The tumor cells are medium sized epithelial cells, dis-
playing little pleomorphism, carcinoma of the papilla limited only 
to the duodenal wall; b) Immunohistochemically, the tumor cells 
expressed the neuroendocrine markers chromogranin A and 
synaptophysin; c) few tumor cells displayed a weak membranous 
immunoreactivity for somatostatin receptor 2 
The tumor was limited to the duodenal wall. Micro-
scopically, the tumor consisted of solid and trabecular 
formations of medium sized epithelial cells, displaying 
only little pleomorphism (Fig. 2, a). The tumor cells 
displayed prominent nucleoli; the cytoplasm was pale 
eosinophilic and occasionally contained clear vacu-
oles. The mitotic activity was low (one mitotic figure 
in 10 high power fields) and the tumor did not show 
any areas of necrosis. 2 of 18 peripancreatic lymph 
nodes contained metastases. The resection margins 
of the surgical specimen were free of tumor confirming 
appropriate margin clearance. Immunohistochemi-
cally, the tumor cells expressed the neuroendocrine 
markers chromogranin A and synaptophysin (Fig. 2, 
b). The proliferative activity (Mib1) was below 2%. 
An expression of the hormones ACTH, glucagon, 
gastrin, insulin, somatostatin, serotonin, or pancreatic 
polypeptide was not detected. Only very few tumor 
cells displayed a weak membranous immunoreactivity 
for somatostatin receptor 2 (Fig. 2, c).
Based on these pathological findings, the diagnosis 
of a well-differentiated neuroendocrine carcinoma 
of the papilla was established. According to the re-
commendations of the European Neuroendocrine 
Tumor Society [6] the tumor was classified as pT2, 
pN1(2/18), G1.
Neuroendocrine tumors arise from hormone pro-
ducing cells in the neuroendocrine system. They may 
originate anywhere in the body where there is neuro-
endocrine tissue. However, the location in the gastro-
intestinal tract is more likely because there are more 
neuroendocrine cells than anywhere else in the body. 
In early stages treatment of choice is surgical resec-
tion which subsequently results in a good prognosis. 
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